Giampaolo Bianchini

Giampaolo Bianchini
申请预约
专科:
肿瘤科 乳腺肿瘤
职业:
肿瘤科医生
医疗机构:
临床肿瘤科 @ 圣拉斐尔科学研究医院
语言:
EN
IT
申请预约

个人简介

Giampaolo Bianchini医生是圣拉斐尔科学研究医院肿瘤内科（科主任是Stefano Cascinu教授）下属的乳腺癌部门负责人。

2000年，Bianchini医生从米兰比可卡大学医学院毕业，2004年在米兰大学完成肿瘤内科专业进修。大学进修期间，他曾担任美国国家癌症研究所（贝塞斯达）、MD安德森癌症中心（休斯顿）和耶鲁癌症中心（纽黑文）等众多美国著名机构的客座专家。

Bianchini医生一直致力于研究早期和转移性乳腺癌患者的治疗，拥有将近二十年的临床经验。此外，他还致力于研发乳腺癌新疗法和免疫治疗方法。

Bianchini医生还是肿瘤内科免疫治疗和转化临床研究的项目主管，参与了众多针对女性乳腺癌患者的研究项目，研究患者对现有药物的反应机制和耐药性，确定新的治疗策略，并确定生物标志物来帮助选择个体化治疗。

此外，他还参与研究患者对免疫治疗药物的反应机制和耐药性，并开发用于治疗乳腺癌和许多其他实体肿瘤的临床试验。

Bianchini医生以作者身份在Journal Clinical Oncology、Lancet Oncology、Cancer Cell、Journal National Cancer Institute、JAMA Oncology和Annals of Oncology等国际期刊上发表过大量文章。H指数为22。他经常参加意大利国内外的行业会议和专题研讨会。

教育背景

米兰比可卡大学

2000年，医学学位

米兰比可卡大学

2004年，肿瘤内科专业学位

多媒体中心

您需要预约吗？

联系我们，我们将为您妥善安排。
申请预约

出版物

Bianchini医生以作者身份在Journal Clinical Oncology、Lancet Oncology、Cancer Cell、journal National Cancer Institute、JAMA Oncology和Annals of Oncology等国际期刊上发表过大量文章。H指数为22。他经常参加意大利国内外的行业会议和专题研讨会。

最新出版物

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
J Clin Oncol 28:4316-23, 2010
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
Cancer Res 70:8852-62, 2010
Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang C, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WK, Gianni L, Pusztai L.
扩展阅读
Biological processes associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
J Natl Cancer Inst 2010 Dec 29
Iwamoto T, Bianchini G, Booser D, QI Y, Coutant C, Shiang C, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes F, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai
扩展阅读
Breast cancer genomics: challenges in interpretation and application.
Oncologist. 2013;18(4):e11-2
Kelly CM, Symmans WF, Andreopoulou E, Bianchini G
扩展阅读
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Breast Cancer Research 2013 15:R86
Bianchini G*, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Muller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Angelica F, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
扩展阅读
An unmeet need: tailoring extended adjuvant endocrine therapy
British Journal of Cancer (2013), 1–4
Bianchini G, Gianni L
扩展阅读
The immune system and response to her2-targeted therapy in breast cancer.
The Lancet Oncology (2014) 15:e58-e68
Bianchini G, Gianni L
扩展阅读
Research-based pam50 subtype predictor identifies higher responses and improved survival outcomes in her2-positive breast cancer in the noah study.
Clin Cancer Res (2014) 20:511-21, 2014
Prat A, Bianchini G, Thomas M, Belousov A, Cheang MCU, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez V, Gianni L, Baselga J
扩展阅读
Immune modulation of pathologic complete response after neoadjuvant her2-directed therapies in the neosphere trial.
Annals of Oncology 26(12): 2429-36
Bianchini G, Pusztai L, Pienkowski T, Im Y-H, Bianchi GV, Tseng L-M, Liu M-C, Lluch A, Galeota E, Magazzù D, Rodríguez J, Oh D-Y, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L
扩展阅读
Subtype specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer.
Clinical Cancer Research 22(2): 337-45
Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, Bianchini G*
扩展阅读
New strategies in breast cancer: immunotherapy.
Clin Cancer Res 22(9): 2105-10
Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G
扩展阅读
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Nat Rev Clin Oncol Nov;13(11):674-690.
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L
扩展阅读
Biomarker analysis of the neosphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of her2-positive breast cancer.
Breast Cancer Res 19(1): 16
Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L
扩展阅读
Association between genomic metrics and immune infiltration in triple-negative breast cancer.
JAMA Oncology (doi:10.1001/jamaoncol.2017.2140)
Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L
扩展阅读
Is trastuzumab single agent obsolete in eraly breast cancer? No.
Breast. 2019 Feb;43:142-145
Bianchini G
扩展阅读

您需要预约吗？

联系我们，我们将为您妥善安排。
申请预约